No Surprise Here: BioNTech's Q3 Results Driven by Its COVID-19 Vaccine Program
How does a company follow an announcement that caused the entire stock market to soar? If it's BioNTech (NASDAQ: BNTX), the company reports well-received quarterly results the next day.
On Monday, BioNTech and its big partner Pfizer (NYSE: PFE) released fantastic interim efficacy results from a late-stage study of COVID-19 vaccine candidate BNT162b2. BioNTech announced third-quarter results before the market opened on Tuesday. Here are the highlights from the German biotech's Q3 update.
Image source: Getty Images.
Source Fool.com
